🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 11 Sep 2026 · EMA CTIS official data

Clinical Trials in Germany

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

208
Recent authorisations
89
Phase III trials
Germany
Selected country
Showing 208 trials
Phase I Immune System Diseases Authorised 10/09/2026

A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)

Systemic lupus erythematosus, sjögren's disease and rheumatoid arthritis
AbbVie Deutschland GmbH & Co. KG
20 participants planned
Germany
2026-526282-25-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 10/09/2026

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Enveda Therapeutics Inc.
12 participants planned
Germany
2026-526184-38-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 09/09/2026

AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma

Asthma
Sanofi-Aventis Recherche & Developpement
346 participants planned
France · Germany
2025-524916-13-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 09/09/2026

C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

Overweight or Obesity
Pfizer Inc.
65 participants planned
Germany · Italy
2026-525318-75-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 09/09/2026

GRT-2U101: A randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-002 in healthy volunteers and patients with chronic spontaneous urticaria after single or multiple intravenous or subcutaneous dosing of GRT-002 (BASALT trial).

Chronic Spontaneous Urticaria
Granite Bio AG
73 participants planned
Germany
2026-526293-16-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 09/09/2026

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight

Body weight management
Camurus AB
150 participants planned
Germany
2026-526951-79-00 on CTIS ↗
Phase II Immune System Diseases Authorised 09/09/2026

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
25 participants planned
Germany · Italy · Slovakia
2026-526241-98-00 on CTIS ↗
Phase I Hemic and Lymphatic Diseases Authorised 08/09/2026

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Follicular Lymphoma
Eli Lilly & Co.
126 participants planned
Italy · France · Germany
2025-523601-16-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 08/09/2026

A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome

Cushing's syndrome
Recordati AG
51 participants planned
Germany · France · Italy
2025-524649-28-00 on CTIS ↗
Phase I Neoplasms Authorised 08/09/2026

A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors

Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Carcinoma (LCNEC) of the lung
Novartis Pharma AG
37 participants planned
France · Spain · Italy · Germany
2024-519111-34-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/09/2026

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)
Argenx
24 participants planned
Germany · Lithuania · Portugal · Slovakia · Hungary · Belgium · France
2026-526218-10-00 on CTIS ↗
Phase III Immune System Diseases Authorised 08/09/2026

EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
6 participants planned
Hungary · France · Finland · Germany
2026-525374-19-00 on CTIS ↗
Phase II Neoplasms Authorised 07/09/2026

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Services Unlimited Company
29 participants planned
Italy · Germany
2026-525170-19-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 07/09/2026

A Long-Term Follow-Up Study to Assess the Safety and Efficacy of B-Cell-Directed Therapy in Patients with Systemic Autoimmune Disease (B-CARE)

systemic autoimmune diseases
Universitaetsklinikum Erlangen AöR
150 participants planned
Germany
2026-526888-37-00 on CTIS ↗
Phase I Immune System Diseases Authorised 07/09/2026

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Rheumatoid arthritis (RA)
Eli Lilly & Co.
15 participants planned
Germany
2025-523980-39-00 on CTIS ↗
Phase I Mental Disorders Authorised 04/09/2026

A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed

Not Applicable
F. Hoffmann-La Roche AG
46 participants planned
Germany
2026-526756-31-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 04/09/2026

An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection

Prostate cancer
Torpedo Pharmaceuticals AG
18 participants planned
Germany
2026-526406-32-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/09/2026

Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)

Type 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.
Novo Nordisk A/S
477 participants planned
Greece · Germany · Italy · Czechia · Poland · Bulgaria · Spain
2026-525209-11-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/09/2026

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
338 participants planned
Belgium · Czechia · Hungary · Sweden · Lithuania · Croatia · Netherlands · Slovakia · Poland · Austria · Norway · France · Italy · Bulgaria · Spain · Germany · Romania · Slovenia · Estonia · Portugal · Greece · Denmark
2026-525913-30-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 02/09/2026

A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).

Type 2 Diabetes mellitus
Tecnimede-Sociedade Tecnico-Medicinal S.A.
760 participants planned
Poland · Germany · Portugal · Italy · Spain
2025-524606-15-00 on CTIS ↗
Phase II Neoplasms Authorised 01/09/2026

A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)

Neoplasm
Universitaetsklinikum Heidelberg AöR
100 participants planned
Germany
2025-523055-55-00 on CTIS ↗
Phase II Eye Diseases Authorised 01/09/2026

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompe' Farmaceutici S.p.A.
171 participants planned
Denmark · Italy · Germany · Hungary · Netherlands · Spain · Belgium · France · Portugal
2025-524748-37-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 01/09/2026

Randomized, controlled, multi-center trial to evaluate the efficacy, tolerability, and safety of an (S)-ibuprofen gel vs. placebo in the local symptomatic and short-term treatment of pain in acute contusions of the soft tissues following blunt trauma

acute contusions of soft tissues
Aponia Laboratories Inc.
120 participants planned
Germany
2025-524451-31-00 on CTIS ↗
Phase III Neoplasms Authorised 01/09/2026

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

Newly Diagnosed Multiple Myeloma
AstraZeneca AB
234 participants planned
Poland · Italy · Denmark · France · Sweden · Germany · Spain
2025-524014-29-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 01/09/2026

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

GBA1-associated Parkinson’s disease
Vanqua Bio Inc.
16 participants planned
Netherlands · France · Spain · Germany
2026-525848-15-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 31/08/2026

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)
Vaderis Therapeutics AG
130 participants planned
Hungary · Netherlands · Germany · Bulgaria · France · Italy · Lithuania · Spain · Belgium
2025-524490-17-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 31/08/2026

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy

Spinal Muscular Atrophy
Biogen Idec Research Limited
24 participants planned
Portugal · Italy · Belgium · Croatia · Hungary · Germany · Ireland · France · Norway · Poland
2025-523857-32-00 on CTIS ↗
Phase II Neoplasms Authorised 31/08/2026

A Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung (ALPINE 2)

Male and female adult patients with locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment
Technische Universitaet Dresden
75 participants planned
Germany
2025-524345-28-00 on CTIS ↗
Phase I Not possible to specify Authorised 31/08/2026

A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity

overweight/obesity
Novo Nordisk A/S
320 participants planned
Germany
2025-521383-35-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 31/08/2026

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Type 2 diabetes (T2D)
Novo Nordisk A/S
175 participants planned
Spain · Hungary · Romania · Slovakia · Poland · Germany
2026-525465-42-00 on CTIS ↗
Phase III Neoplasms Authorised 28/08/2026

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

Resected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer
F. Hoffmann-La Roche AG
178 participants planned
France · Spain · Austria · Greece · Portugal · Belgium · Italy · Germany · Netherlands
2025-524263-21-01 on CTIS ↗
Phase IV Digestive System Diseases Authorised 28/08/2026

A prospective, exploratory, parallel-group, low-intervention, phase IV, randomized, double-blind, placebo-controlled, multi-center, national, 2-arm trial to investigate efficacy and safety of Amara-Tropfen (Amara drops) in patients with irritable bowel syndrome (IBS)

Irritable Bowel Syndrome
Weleda AG
106 participants planned
Germany
2026-526668-19-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/08/2026

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)
Institut De Recherches Internationales Servier IRIS
38 participants planned
Netherlands · Spain · Germany · Italy · France · Finland
2025-525128-88-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 27/08/2026

Relative oral bioavailability and tolerability of hydrocortisone from 2-dimensionally printed orodispersible films in children and adolescents with primary adrenal insufficiency (REPLACE trial)

adrenal insufficiency
Universitaetsklinikum Heidelberg AöR
8 participants planned
Germany
2026-526416-37-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/08/2026

A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease

Fabry disease
Idorsia Pharmaceuticals Ltd.
8 participants planned
Germany · France
2026-525207-27-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 26/08/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
156 participants planned
Italy · Belgium · Denmark · Austria · Greece · Germany · France · Netherlands · Portugal · Poland · Spain
2025-521901-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
Pfizer Inc.
33 participants planned
Spain · France · Italy · Ireland · Germany · Poland
2025-524825-42-00 on CTIS ↗
Phase II Neoplasms Authorised 26/08/2026

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Gastrointestinal Cancers
Genmab A/S
67 participants planned
Italy · Belgium · France · Spain · Denmark · Netherlands · Germany
2025-524130-26-00 on CTIS ↗
Phase III Immune System Diseases Authorised 25/08/2026

A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · France · Greece · Poland · Spain · Italy · Germany
2025-524757-14-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/08/2026

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

narcolepsy
Harmony Biosciences Management Inc.
92 participants planned
Belgium · Italy · Germany · France · Spain · Poland
2025-523821-17-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 25/08/2026

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Apollo Therapeutics Limited
138 participants planned
Hungary · Czechia · Germany · Bulgaria · Poland · Spain
2026-525673-39-00 on CTIS ↗
Phase II Neoplasms Authorised 25/08/2026

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

Solid tumor
Bristol-Myers Squibb Services Unlimited Company
116 participants planned
Greece · Hungary · Poland · Belgium · Spain · Netherlands · Germany · France · Portugal · Italy · Romania
2025-524905-34-00 on CTIS ↗
Phase I/II Bacterial Infections and Mycoses Authorised 24/08/2026

A combined phase I/IIa trial to investigate the safety and pharmacokinetics of StaphAcute in healthy participants and patients with Staphylococcus aureus bacteremia - StaphAcute

Phase IIa: patients with methicillin susceptible (MSSA) or methicillin resistant (MRSA) Staphylococcus aureus bacteremia (SAB)., Phase I: first in human application in healthy particpants, dose escalation study.
University Of Cologne
54 participants planned
Germany
2024-511586-10-01 on CTIS ↗
Phase III Neoplasms Authorised 24/08/2026

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Pancreatic Adenocarcinoma
Revolution Medicines Inc.
281 participants planned
Sweden · Spain · France · Poland · Italy · Norway · Belgium · Germany · Czechia · Austria · Netherlands · Denmark
2025-524928-21-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 21/08/2026

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Polycythemia Vera
Deciphera Pharmaceuticals Inc.
106 participants planned
Austria · Czechia · Italy · Portugal · Germany · France · Hungary · Spain · Poland
2025-524669-25-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Gastrointestinal Stromal
Glaxosmithkline Research & Development Limited
302 participants planned
Italy · Portugal · Germany · Sweden · Poland · Romania · Finland · Greece · Norway · Spain · Netherlands · France · Hungary
2025-524934-24-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 21/08/2026

A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients

Acute Incomplete Cervical Spinal Cord Injury
NovaGo Therapeutics AG
84 participants planned
Germany
2026-526089-26-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/08/2026

A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors

Solid tumors
Immatics US Inc.
9 participants planned
Germany
2026-525827-25-00 on CTIS ↗
Phase III Eye Diseases Authorised 21/08/2026

A Randomized, Double-Masked, Placebo-Controlled Study Assessing the Efficacy and Safety Of Privosegtor (OCS-05) as add-on to IV Methylprednisolone in Participants with Optic Neuritis (PIONEER 1)

Optic Neuritis
Oculis Operations SARL
82 participants planned
Italy · Germany · France · Poland · Spain
2025-525075-91-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
K-Group Beta Inc.
197 participants planned
Germany · Spain · Italy · Belgium · Poland · France · Ireland
2025-524641-27-00 on CTIS ↗
Phase III Neoplasms Authorised 20/08/2026

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals Inc.
108 participants planned
Italy · Spain · Poland · France · Norway · Greece · Germany
2025-523252-31-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 20/08/2026

Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL "Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study" A prospective non-randomized multicenter phase I study

relapsed/ refractory Primary central nervous system lymphoma (r/r PCNSL)
Medizinische Universitaet Innsbruck
18 participants planned
Germany · Austria
2024-520342-28-00 on CTIS ↗
Phase I Neoplasms Authorised 20/08/2026

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Recurrent Glioblastoma
Heinrich-Heine-Universitaet Duesseldorf
6 participants planned
Germany
2026-525397-19-00 on CTIS ↗
Phase III Eye Diseases Authorised 20/08/2026

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
64 participants planned
Belgium · France · Spain · Italy · Germany
2026-525296-60-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 20/08/2026

J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D

Irritable Bowel Syndrome Diarrhea
Eli Lilly & Co.
186 participants planned
Germany · Poland · Spain · Belgium
2025-524973-17-00 on CTIS ↗
Phase III Mental Disorders Authorised 19/08/2026

JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)

Depressive Disorder, Major
Eli Lilly & Co.
228 participants planned
Poland · Greece · Spain · Germany
2025-522310-24-00 on CTIS ↗
Phase III Immune System Diseases Authorised 18/08/2026

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis

Ocular Myasthenia Gravis
UCB Biopharma
46 participants planned
Hungary · Greece · Italy · Spain · Germany · Poland · France
2025-524756-54-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 18/08/2026

A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity

overweight, obesity
Boehringer Ingelheim International GmbH
35 participants planned
Germany
2026-526090-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 18/08/2026

A clinical research study investigating how the body processes the new compound afabicin in people with kidney problems and people with normal kidney function

Renal Impairment
Debiopharm International S.A.
60 participants planned
Germany
2026-526916-35-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 18/08/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
295 participants planned
Netherlands · Denmark · Germany · Spain
2025-525102-38-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/08/2026

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.

Dementia Alzheimer's type
Sanofi-Aventis Recherche & Developpement
266 participants planned
Spain · Germany
2025-524581-14-00 on CTIS ↗
Phase I Neoplasms Authorised 17/08/2026

A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

Metastatic castration resistant prostate cancer
Novartis Pharma AG
26 participants planned
France · Italy · Spain · Germany
2025-524080-20-00 on CTIS ↗
Phase III Neoplasms Authorised 17/08/2026

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

Small-cell lung cancer, limited stage
Norges Teknisk-Naturvitenskapelige Universitet NTNU
426 participants planned
Denmark · Finland · Estonia · Germany · Lithuania · Sweden · Norway · Netherlands
2026-525513-31-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 17/08/2026

C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Pneumoccoccal Immunisation
Pfizer Inc.
1345 participants planned
Spain · Finland · Poland · Germany · Greece · Hungary · Italy
2025-523447-35-02 on CTIS ↗
Phase I/II Neoplasms Authorised 17/08/2026

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
30 participants planned
Italy · Germany · Spain · Finland · France
2025-524915-36-00 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 17/08/2026

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC)
BioNTech SE
183 participants planned
Belgium · Spain · Italy · Poland · Germany · Hungary
2025-524445-27-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 17/08/2026

A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared with Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients with Hypercholesterolaemia.

Hypercholesterolaemia
AstraZeneca AB
60 participants planned
Germany
2026-526258-15-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 14/08/2026

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)

Severe asthma
Kinaset Therapeutics Inc.
350 participants planned
Czechia · Bulgaria · Romania · Hungary · Germany · Poland · Greece
2023-509125-41-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 14/08/2026

An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases

ANCA associated vasculitis (AAV), Immune thrombocytopenic purpura (ITP), Multiple sclerosis (MS), Rheumatoid arthritis (RA), Pemphigus vulgaris (PV), Systemic sclerosis (SSc), Inflammatory idiopathic Myositis (IIM)
Universitaetsklinikum Tuebingen AöR
36 participants planned
Germany
2024-519491-60-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 14/08/2026

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)

Diagnosis of primary ITP according to the 2019 International Consensus Report that is previously untreated and requires treatment
Amgen Inc.
42 participants planned
Spain · Hungary · Germany
2026-525454-11-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 13/08/2026

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]

locally advanced or metastatic small bowel adenocarcinoma
Charite Universitaetsmedizin Berlin KöR
112 participants planned
Germany
2025-524131-39-00 on CTIS ↗
Phase II Neoplasms Authorised 13/08/2026

A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

HR-positive/HER2-negative advanced breast cancer
Medica Scientia Innovation Research S.L.
25 participants planned
Spain · Italy · Germany
2026-525328-10-00 on CTIS ↗
Phase III Neoplasms Authorised 13/08/2026

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

Breast Cancer
AstraZeneca AB
79 participants planned
Poland · Spain · France · Germany · Italy
2025-523444-12-00 on CTIS ↗
Phase III Diagnosis Authorised 12/08/2026

International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies

Patients suffering from rhinitis / rhinoconjunctivitis, with well-controlled mild-to-moderate asthma or without asthma, due to the exposure to any of the allergen sources under investigation, for at least 2 years in case of seasonal allergenic sources or for at least 1 year in case of perennial allergenic sources.
ROXALL Medizin GmbH
140 participants planned
Germany · Spain
2025-524676-32-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 12/08/2026

A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants

This clinical trial is performed in healthy participants; the planned indication is: Neurofibromatosis Type I
Merck Healthcare KGaA
17 participants planned
Germany
2026-526403-30-00 on CTIS ↗
Phase I Neoplasms Authorised 10/08/2026

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp.
60 participants planned
Italy · Belgium · Germany · France · Spain
2026-525217-31-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 10/08/2026

A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function

Heart failure with preserved ejection fraction
Novo Nordisk A/S
54 participants planned
Germany
2026-525271-57-00 on CTIS ↗
Phase II Immune System Diseases Authorised 10/08/2026

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA) (Breakfree-AiCE)

Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
Celgene Corp.
3 participants planned
Germany · Denmark
2025-524993-41-00 on CTIS ↗
Phase III Hormonal diseases Authorised 07/08/2026

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Graves' Disease (GD)
Argenx
145 participants planned
Italy · Czechia · Spain · Denmark · Belgium · Romania · Latvia · France · Germany · Greece · Sweden · Poland · Lithuania · Bulgaria
2025-523333-26-00 on CTIS ↗
Phase I Not possible to specify Authorised 07/08/2026

A study in healthy men to test whether carbamazepine influences the amount of verducatib in the blood

Healthy
Boehringer Ingelheim International GmbH
20 participants planned
Germany
2026-525821-19-00 on CTIS ↗
Phase I Not possible to specify Authorised 07/08/2026

A study in healthy people to test how Zongertinib is taken up in the body when given as tablets made by two different manufacturers with or without food

Healthy
Boehringer Ingelheim International GmbH
56 participants planned
Germany
2026-525696-77-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 06/08/2026

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

Atrial fibrillation
Bayer AG
105 participants planned
Belgium · Netherlands · Germany · Poland · Italy · Hungary · Bulgaria
2025-523807-31-00 on CTIS ↗
Phase I Not possible to specify Authorised 06/08/2026

A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants

Healthy volunteers, therapeutic indication not studied
Haleon CH SARL
52 participants planned
Germany
2025-524663-20-00 on CTIS ↗
Phase I Not possible to specify Authorised 06/08/2026

A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body

Healthy
Boehringer Ingelheim International GmbH
36 participants planned
Germany
2025-524773-16-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 05/08/2026

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

Chronic Kidney Disease, Heart Failure, Coronary Artery disease
Novartis Pharma AG
43 participants planned
Germany
2026-525974-21-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 04/08/2026

A Phase IV, Randomized Controlled Trial to Evaluate the Effects of Resistance Training Versus Usual Care on Thigh Muscle Volume During Treatment with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Adults with Obesity

Obesity
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
150 participants planned
Germany
2026-526200-69-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis
AstraZeneca AB
139 participants planned
Poland · Hungary · Netherlands · Germany · Spain · Greece · Bulgaria · Italy · France · Denmark
2025-525016-41-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

type 2 diabetes mellitus
AstraZeneca AB
200 participants planned
Poland · Germany · Bulgaria · Czechia
2025-523935-20-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

type 2 diabetes mellitus
AstraZeneca AB
183 participants planned
Germany · Bulgaria · Spain · Denmark
2025-523940-12-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

type 2 diabetes mellitus
AstraZeneca AB
360 participants planned
Slovakia · Poland · Czechia · Germany · Hungary · Greece · Denmark
2025-523941-81-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 03/08/2026

Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT

Full-thickness cartilage defects of the knee
Medical Center - University Of Freiburg
166 participants planned
Germany
2026-526179-49-00 on CTIS ↗
Phase I Neoplasms Authorised 03/08/2026

A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corp.
40 participants planned
Italy · Belgium · Germany
2026-525360-18-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
179 participants planned
Denmark · Hungary · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Romania · Croatia · Poland · Estonia · Italy · Lithuania
2025-523884-39-00 on CTIS ↗
Phase I Immune System Diseases Authorised 03/08/2026

Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)

Therapy-resistant and progressing lung fibrosis in the course of an autoantibody-positive autoimmune disease like Systemic Sclerosis, ANCA-associated Vasculitis, seropositive Rheumatoid Arthritis, Sjögren’s disease, anti-Synthetase Syndrome or other autoimmune diseases
Universitaetsklinikum Heidelberg AöR
10 participants planned
Germany
2024-519592-26-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
194 participants planned
Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece
2026-525922-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
302 participants planned
France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 30/07/2026

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

Renal Impairment
Sanofi-Aventis Recherche & Developpement
8 participants planned
Germany
2026-525707-27-00 on CTIS ↗
Phase I/II Skin and Connective Tissue Diseases Authorised 29/07/2026

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age

Acne
Sanofi Pasteur Inc.
189 participants planned
Spain · Germany · Poland
2025-521740-38-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.
AstraZeneca AB
2343 participants planned
Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia
2026-526304-79-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/07/2026

An Open-label Phase 1 Study in Healthy Adult Participants to Investigate the Effect of Itraconazole on the Blood Levels of Engasertib

This clinical trial is performed in healthy participants; the planned indication: Treatment of Hereditary hemorrhagic telangiectasia (HHT)
Vaderis Therapeutics AG
27 participants planned
Germany
2026-526311-11-00 on CTIS ↗
Phase II Neoplasms Authorised 27/07/2026

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
26 participants planned
Spain · France · Germany · Norway
2025-522757-19-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
125 participants planned
Italy · Greece · Spain · Belgium · France · Austria · Germany
2025-523819-11-00 on CTIS ↗
Phase I Not possible to specify Authorised 27/07/2026

A study in healthy people to measure how different doses of verducatib affect the heart

Healthy volunteer trial
Boehringer Ingelheim International GmbH
56 participants planned
Germany
2026-525813-30-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)

Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitus
AstraZeneca AB
1010 participants planned
Spain · Germany · Italy · Poland
2025-524688-19-00 on CTIS ↗
Phase III Neoplasms Authorised 27/07/2026

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
233 participants planned
Poland · Italy · Germany · France · Spain
2025-523960-19-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 24/07/2026

Immune Cell Therapy for People with Early, Active Multiple Sclerosis

Newly diagnosed highly-active Multiple Sclerosis
Medizinische Hochschule Hannover
10 participants planned
Germany
2025-522409-39-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/07/2026

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

Spinal Muscular Atrophy
Biogen Idec Research Limited
40 participants planned
Finland · Spain · Italy · Poland · Ireland · Germany · France
2025-524054-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

Chronic kidney disease (CKD) in adults, with specified ranges of eGFR and albuminuria (UACR), irrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.
AstraZeneca AB
1600 participants planned
Czechia · Italy · Hungary · Romania · Bulgaria · Sweden · Denmark · Poland · Spain · Norway · Finland · Greece · France · Germany
2025-523994-41-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 23/07/2026

A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Genentech Inc.
104 participants planned
Germany
2025-525042-22-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 23/07/2026

IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
91 participants planned
Germany · Spain
2026-525185-21-00 on CTIS ↗
Phase III Hormonal diseases Authorised 23/07/2026

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc.
71 participants planned
Czechia · Germany · Sweden · Portugal · Romania · Bulgaria · Italy · Austria · Spain
2025-524282-24-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 23/07/2026

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease

Huntington’s Disease
Skyhawk Therapeutics Inc.
110 participants planned
Germany · Spain
2025-522263-14-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 22/07/2026

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
4 participants planned
France · Italy · Germany · Spain
2025-524418-27-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 22/07/2026

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis

Refractory, difficult-to-treat Rheumatoid Arthritis
Bristol-Myers Squibb Services Unlimited Company
21 participants planned
Poland · Italy · Spain · Germany
2025-520666-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 22/07/2026

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

type 2 diabetes mellitus
AstraZeneca AB
335 participants planned
Poland · Hungary · Italy · Bulgaria · Germany
2025-523933-24-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/07/2026

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Alnylam Pharmaceuticals Inc.
17 participants planned
Italy · Netherlands · Spain · Germany · Ireland
2025-523390-42-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis
Ipsen Bioscience Inc.
127 participants planned
Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway
2026-525242-29-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 21/07/2026

Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex

Intestinal colonization with vancomycin-resistant enterococci (VRE)
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
42 participants planned
Germany
2026-525632-41-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

HIV-1
Gilead Sciences Inc.
183 participants planned
Poland · Italy · France · Spain · Germany · Netherlands
2025-524336-19-00 on CTIS ↗
Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

HIV-1
Gilead Sciences Inc.
183 participants planned
Netherlands · Poland · Germany · France · Spain · Italy
2025-524335-39-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 21/07/2026

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

Lichen Sclerosus
Leo Pharma A/S
205 participants planned
Italy · France · Spain · Poland · Germany
2025-524873-17-00 on CTIS ↗
Phase II Neoplasms Authorised 21/07/2026

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Breast Neoplasms
Eli Lilly & Co.
361 participants planned
Belgium · France · Italy · Germany
2025-523258-15-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 20/07/2026

Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

biochemical relapse of prostate cancer
Universitaetsklinikum Tuebingen AöR
84 participants planned
Germany
2025-522144-41-00 on CTIS ↗
Phase II Neoplasms Authorised 20/07/2026

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

Multiple Myeloma (MM)
F. Hoffmann-La Roche AG
45 participants planned
Germany
2026-525736-42-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 20/07/2026

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB
158 participants planned
Germany · Italy · Spain · France · Sweden
2025-523908-75-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG
368 participants planned
Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1
Alkermes Inc.
116 participants planned
Sweden · Finland · Belgium · Spain · Austria · Netherlands · France · Norway · Germany · Italy · Poland
2025-524711-36-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 20/07/2026

An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL

Ph-negative CD19 positive B-precursor ALL patients in CR1 with molecular failure defined as MRD of 10-4 or greater after induction II of front-line therapy
Goethe University Frankfurt
20 participants planned
Germany
2025-524169-26-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/07/2026

A phase I/IIa safety, dose finding and feasibility trial of CD30/CEA CART in patients with liver metastases from CEA positive colorectal adenocarcinoma

Colorectal Adenocarcinoma
Universitaetsklinikum Regensburg AöR
18 participants planned
Germany
2026-526225-18-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 14/07/2026

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

Asthma
Glaxosmithkline Research & Development Limited
229 participants planned
Ireland · Spain · Germany · Czechia · Bulgaria · France · Belgium · Romania · Italy
2025-524463-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 14/07/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

Acute Ischemic Stroke
Takeda Development Center Americas Inc.
67 participants planned
Greece · Belgium · France · Germany
2025-522734-31-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 14/07/2026

Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial

Peripheral arterial disease, Coronary artery atherosclerotic heart disease, Hypercholesterolaemia
Medical University Of Graz
160 participants planned
Germany · Austria
2026-525917-29-00 on CTIS ↗
Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer
Merck Healthcare KGaA
323 participants planned
Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria
2025-524648-37-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc.
97 participants planned
France · Portugal · Spain · Slovakia · Italy · Germany · Poland
2025-524448-36-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
337 participants planned
Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain
2025-525088-34-00 on CTIS ↗
Phase I Not possible to specify Authorised 14/07/2026

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Metastatic triple negative breast cancer
Universitaetsklinikum Aachen AöR
18 participants planned
Germany
2025-524027-49-00 on CTIS ↗
Phase II Immune System Diseases Authorised 13/07/2026

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

Antibody-mediated Kidney Disease
AstraZeneca AB
17 participants planned
France · Germany · Italy · Belgium · Poland · Spain
2025-524139-38-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 13/07/2026

Model-informed precision dosing for linezolid: a randomized clinical trial

Bacterial infection (pneumonia, skin or soft tissue infection) requiring treatment with linezolid in patients in intensive care unit
University Medical Center Hamburg-Eppendorf
30 participants planned
Germany
2024-517888-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 13/07/2026

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Multiple Myeloma (MM), Multiple Myeloma (MM)
AbbVie Deutschland GmbH & Co. KG
88 participants planned
Germany · Poland · Czechia · Belgium · France · Greece · Sweden · Portugal · Italy
2025-525105-20-00 on CTIS ↗
Phase II Neoplasms Authorised 13/07/2026

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc.
20 participants planned
Netherlands · Germany · Spain
2026-525282-50-00 on CTIS ↗
Phase I Neoplasms Authorised 13/07/2026

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma
Janssen Cilag International
175 participants planned
France · Spain · Germany · Denmark · Belgium
2026-525234-39-00 on CTIS ↗
Phase II Virus Diseases Authorised 13/07/2026

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

Long-term persistence of SARS-CoV-2
Goethe University Frankfurt
24 participants planned
Germany · Spain
2025-524442-10-00 on CTIS ↗
Phase I Hormonal diseases Authorised 10/07/2026

A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women

Vasomotor symptoms as a sex hormone-dependent disorder in women and men
Bayer AG
30 participants planned
Germany
2026-525569-30-00 on CTIS ↗
Phase III Neoplasms Authorised 09/07/2026

AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

acute lymphoblastic leukemia in children and adolescents
Universitaetsklinikum Schleswig-Holstein AöR
2250 participants planned
Germany
2025-522190-11-01 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 09/07/2026

Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)

bone and joint infections
University Of Cologne
280 participants planned
Germany
2026-526270-17-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/07/2026

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
Argenx
29 participants planned
Greece · Italy · Germany · Belgium · Netherlands · Spain · Poland
2025-522939-33-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 08/07/2026

Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus – a first-in-human proof-of-concept microbiome intervention study

Persistent or intermitting colonization of the nose with Staphylococcus aureus
Universitaetsklinikum Tuebingen AöR
36 participants planned
Germany
2024-514894-22-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 08/07/2026

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy

Narcolepsy
Eisai Limited
51 participants planned
Belgium · Italy · Spain · Germany
2025-523503-30-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 08/07/2026

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Alnylam Pharmaceuticals Inc.
5 participants planned
Netherlands · Sweden · Germany
2025-524967-19-00 on CTIS ↗
Phase I Not possible to specify Authorised 08/07/2026

A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity

Healthy
Boehringer Ingelheim International GmbH
44 participants planned
Germany
2026-526307-30-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 07/07/2026

Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine

Gonorrhea
LimmaTech Biologics AG
142 participants planned
Germany
2026-526168-19-00 on CTIS ↗
Phase II Neoplasms Authorised 07/07/2026

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Bristol-Myers Squibb Services Unlimited Company
123 participants planned
Belgium · Ireland · Germany · Norway · Italy · France · Spain
2025-524285-18-00 on CTIS ↗
Phase I Neoplasms Authorised 07/07/2026

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma
Eli Lilly & Co.
64 participants planned
Germany · Netherlands
2025-521887-37-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
20 participants planned
Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal
2025-523369-32-00 on CTIS ↗
Phase III Neoplasms Authorised 07/07/2026

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

Multiple Myeloma
F. Hoffmann-La Roche AG
133 participants planned
France · Germany · Italy · Greece · Denmark · Czechia · Spain · Poland
2025-524028-23-00 on CTIS ↗
Phase III Neoplasms Authorised 06/07/2026

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG
194 participants planned
Portugal · Spain · France · Italy · Germany · Austria
2025-522563-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
613 participants planned
Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France
2024-518016-39-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
550 participants planned
Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain
2024-518213-25-00 on CTIS ↗
Phase III Mental Disorders Authorised 01/07/2026

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

First Episode Psychosis (FEP)
University Of Oxford
156 participants planned
Netherlands · Greece · Germany · Italy · Austria · Spain
2025-521929-32-01 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
206 participants planned
Poland · Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
19 participants planned
Belgium · Netherlands · Spain · Germany · Italy
2025-523127-21-00 on CTIS ↗
Phase I Not possible to specify Authorised 01/07/2026

A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood

Healthy
Boehringer Ingelheim International GmbH
16 participants planned
Germany
2026-525549-60-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
257 participants planned
Finland · Belgium · Hungary · France · Denmark · Austria · Germany · Italy · Spain · Czechia · Norway · Poland
2025-522167-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
45 participants planned
Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc.
165 participants planned
Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

Dravet Syndrome
Ionis Pharmaceuticals Inc.
11 participants planned
Spain · France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/06/2026

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

Infectious endocarditis caused by Gram-positive cocci (staphylococci, enterococci, streptococci)
Friedrich-Schiller-Universitaet Jena
166 participants planned
Germany
2026-526149-91-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited
111 participants planned
France · Spain · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/06/2026

A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults

Not applicable, healthy volunteers
Dr. Falk Pharma GmbH
32 participants planned
Germany
2025-523778-17-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
57 participants planned
Germany · Romania · France · Bulgaria · Belgium · Spain · Poland · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
54 participants planned
Spain · Belgium · France · Germany · Slovakia · Romania · Bulgaria · Italy · Poland · Greece
2025-523871-44-00 on CTIS ↗
Phase III Neoplasms Authorised 29/06/2026

AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
243 participants planned
Greece · Portugal · Germany · Belgium · Spain
2025-521712-19-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Non-small Cell Lung Cancer
AstraZeneca AB
11 participants planned
Spain · Germany
2025-523599-21-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 29/06/2026

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

Non small cell lung cancer
Radboud universitair medisch centrum Stichting
40 participants planned
Netherlands · Germany
2025-524791-30-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

Solid Tumors
Revolution Medicines Inc.
252 participants planned
France · Poland · Ireland · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 26/06/2026

Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Atrial Fibrillation
Universitaetsspital Basel
1 participants planned
Germany
2024-516033-12-00 on CTIS ↗
Phase III Therapeutics Authorised 26/06/2026

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial

Patients after the first year following liver transplantation
Medizinische Hochschule Hannover
150 participants planned
Germany
2025-524312-11-00 on CTIS ↗
Phase I Immune system processes Authorised 25/06/2026

A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease

B-cell–mediated autoimmune diseases
Oblenio Bio Inc.
57 participants planned
Germany · Romania
2026-525621-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 25/06/2026

Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

Rheumatoid Arthritis
Jade Biosciences Inc.
24 participants planned
Romania · Bulgaria · Germany
2025-524746-96-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 24/06/2026

A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590

Weight management
Zealand Pharma A/S
88 participants planned
Germany
2026-525978-19-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement
41 participants planned
Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG
9 participants planned
Poland · Germany · France
2025-524164-37-00 on CTIS ↗
Phase III Neoplasms Authorised 23/06/2026

A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer

Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)
Silexion Therapeutics Ltd.
10 participants planned
Germany
2025-525157-39-00 on CTIS ↗
Phase II Neoplasms Authorised 23/06/2026

Efficacy of asciminib in chronic phase CML patients with T315l mutations

Chronic Myeloid Leukemia
Friedrich-Schiller-Universitaet Jena
50 participants planned
Germany
2025-523491-23-00 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Hereditary Angioedema
Adarx Pharmaceuticals Inc.
45 participants planned
Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
486 participants planned
Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
88 participants planned
Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/06/2026

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Colitis ulcerative
Merck Sharp & Dohme LLC
44 participants planned
Italy · Greece · Netherlands · Poland · Germany · France
2025-523479-49-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 22/06/2026

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis
Trace Neuroscience Inc.
20 participants planned
Germany · Netherlands
2025-523111-11-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 22/06/2026

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited
29 participants planned
Netherlands · Germany · Italy · Sweden · France
2025-522275-28-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/06/2026

Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events

Coronary atherosclerosis
Daiichi Sankyo Europe GmbH
103 participants planned
Italy · Spain · Germany
2025-524625-41-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

Systemic Sclerosis
Celgene Corp.
37 participants planned
Spain · Germany · France · Italy · Belgium
2025-524337-11-00 on CTIS ↗
Phase I Immune System Diseases Authorised 19/06/2026

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

healthy volunteers, immunological diseases
Sanofi-Aventis Recherche & Developpement
147 participants planned
Germany
2026-526014-87-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 19/06/2026

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)

Marginal Zone Lymphoma
Universitaetsklinikum Ulm AöR
53 participants planned
Germany
2025-524879-23-00 on CTIS ↗
Phase III Neoplasms Authorised 18/06/2026

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I.
212 participants planned
Spain · Germany · Italy
2025-524048-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR
110 participants planned
Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 17/06/2026

A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system

Demyelinating diseases
Medizinische Hochschule Hannover
116 participants planned
Germany · Austria
2025-523654-13-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company
318 participants planned
Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB
516 participants planned
France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Stage I NSCLC
Merck Sharp & Dohme LLC
283 participants planned
Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
228 participants planned
Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement
177 participants planned
France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Limb Girdle Muscular Dystrophy (LGMD) Type 2I
ML Bio Solutions Inc.
35 participants planned
Germany · Denmark · Netherlands · Italy · Norway
2025-524371-23-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

C3 Glomerulopathy (C3G), Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum AB (publ)
82 participants planned
France · Italy · Spain · Germany · Belgium
2025-524487-37-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC
88 participants planned
Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
210 participants planned
Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 11/06/2026

J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn Disease
Eli Lilly & Co.
37 participants planned
Italy · Germany · Hungary · Poland · Belgium
2025-524112-11-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/06/2026

Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week, multicenter, open-label, randomized controlled trial

Crohn’s disease
Universitaetsklinikum Schleswig-Holstein AöR
320 participants planned
Germany
2026-525191-26-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/germany (Accessed: 11 September 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.